Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06651580 · ClinicalTrials.gov registry record

Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study

A clinical trial of Chronic Pancreatitis and Recurrent Acute Pancreatitis, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
1,600
Enrollment target
20
Study locations

NCT06651580: Recruiting study of Chronic Pancreatitis and Recurrent Acute Pancreatitis, sponsored by M.D. Anderson Cancer Center.

NCT06651580 is a study of Chronic Pancreatitis and Recurrent Acute Pancreatitis that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 1,600 participants, above the 651-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (146% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06651580, a study of Chronic Pancreatitis and Recurrent Acute Pancreatitis, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
1,600 participants
Enrollment target
20
Study locations

Study Summary

This clinical trial collects blood, saliva, urine, or stool samples to help identify possible genetic mutations that may increase a person's chance at developing pancreatic cancer. Finding genetic markers among pediatric patients with acute recurrent pancreatitis and chronic pancreatitis may help identify patients who are at risk of pancreatic cancer.

Primary Outcome

Two-sample t-test or Wilcoxon rank-sum test will be used for the continuous/ordinal variables and Pearson Chi-square test for the categorical variables. The variables that suggest differences between ARP and CP (p value \< 0.15) will be included as independent variables in a multivariable logistic regression analysis for CP progression.

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration

Study Locations (20)

California

  • Children's Hospital Los Angeles - Los Angeles
  • Cedars Sinai Medical Center - Los Angeles
  • UCSF Benioff Children's Hospital Oakland - Oakland
  • Stanford Cancer Institute Palo Alto - Palo Alto

Texas

  • University of Texas Southwestern/Children's Medical Center - Dallas
  • M D Anderson Cancer Center - Houston
  • Texas Children's Hospital - Houston

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati
  • Nationwide Children's Hospital - Columbus

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia
  • Children's Hospital of Pittsburgh of UPMC - Pittsburgh

Colorado

  • University of Colorado - Denver

Georgia

  • Emory University Hospital/Winship Cancer Institute - Atlanta

Indiana

  • Riley Hospital for Children - Indianapolis

Iowa

  • University of Iowa/Holden Comprehensive Cancer Center - Iowa City

Trial Details

FieldValue
Enrollment Target 1,600 participants
Start Date 2021-04-01
Est. Completion 2027-02-02
M.D. Anderson Cancer Center

2,692 total trials

What NCT06651580 shows while recruiting

NCT06651580 is an observational study that tracks outcomes without assigning an intervention. Its 1,600 participants enrollment target places it among the larger protocols in the corpus, above the 651-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (146% higher).

The record links to 3 conditions, with Chronic Pancreatitis appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.

NCT06651580 names 20 study sites across 13 states, led by California, Texas, Ohio.

Frequently Asked Questions

What is clinical trial NCT06651580 about?

NCT06651580 is a clinical study titled "Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study". This clinical trial collects blood, saliva, urine, or stool samples to help identify possible genetic mutations that may increase a person's chance at developing pancreatic cancer. Finding genetic markers among pediatric patients with acute recurrent pancreatitis and chronic pancreatitis may help id...

What is the current status of trial NCT06651580?

This trial is currently recruiting. The enrollment target is 1,600 participants. The study started on 2021-04-01. Estimated completion is 2027-02-02.

What conditions does trial NCT06651580 study?

This clinical trial studies the following conditions: Chronic Pancreatitis, Recurrent Acute Pancreatitis, Exocrine Pancreas Carcinoma.

What interventions are being tested in trial NCT06651580?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER).

Who is sponsoring clinical trial NCT06651580?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06651580 being conducted?

This trial has 20 study locations across California, Colorado, Georgia, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pancreatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06651580's enrollment target sits among peer trials

1,600 2nd of 42 the highest of 42 other Chronic Pancreatitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Pancreatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00646022 · 1,600 participants

    Natural History of Familial Carcinoid Tumor

  • NCT03109197 · 1,600 participants

    Sudden Unexplained Death in Childhood (SUDC) Registry

  • NCT03511118 · 1,600 participants

    Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

  • NCT04314401 · 1,600 participants

    National Cancer Institute "Cancer Moonshot Biobank"

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06651580, the US trial registry maintained by the National Library of Medicine. NCT06651580 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.